Pharma/biotech companies are increasingly looking to access large-scale data sets to fill gaps in their computational biology capabilities. Be prepared for the investment.
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- Enhancing Gene And Cell Therapies With Circular RNA-Based Gene Expression
- FDA Explains How To Respond To Form 483 Observations In New Draft Guidance
- Organizing Digital Systems Around Novel Modalities
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?
- Is Your AI Model Trustworthy And Credible In GMP Processes?
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-2155418067-bioreactor-scientist-ipad-beaker]( "iPSC Aggregate Culture In Bioreactors Equipped With 8-Blade Impellers")
iPSC Aggregate Culture In Bioreactors Equipped With 8-Blade ImpellersControlled aggregation, oxygen management, and scalable workflows drive consistent iPSC expansion. Parallelized systems and precise parameter control improve reproducibility for faster optimization and confident transitions.
-
![Test Tube Blood Samples GettyImages-177440807]( "Immunophenotyping Of Normal Whole Blood Using A 12-Color BD Horizon™ Chroma Research Panel On The BD FACSDuet™ Premium Sample Preparation System Integrated With The BD FACSLyric™ Flow Cytometer")
Immunophenotyping Of Normal Whole Blood Using A 12-Color BD Horizon™ Chroma Research Panel On The BD FACSDuet™ Premium Sample Preparation System Integrated With The BD FACSLyric™ Flow CytometerIn this study, a fully automated workflow utilizing the BD FACSDuet™ Premium Sample Preparation System integrated with the BD FACSLyric™ Flow Cytometer was assessed and compared to manual processing.
-
![Cytiva Minimate]( "Benchmarking Filtration Performance Of TFF Cassettes")
Benchmarking Filtration Performance Of TFF CassettesOptimize your protein purification workflow with tangential flow filtration by comparing membrane performance and exploring how protein concentration impacts flux and MWCO selection in lab-scale systems.
-
![GettyImages-2190247072-laboratory-vials-analysis-scientist]( "Optimized Urine Liquid Biopsy Workflow")
Optimized Urine Liquid Biopsy WorkflowUrine-derived cell-free DNA is revolutionizing liquid biopsy research to offer a non-invasive, accessible tool for early disease detection, monitoring, and comprehensive diagnostics across oncology.
-
![GettyImages-1429005105-scientist-ipad-software-management]( "Guiding Principles For Process Development And IND Readiness")
Guiding Principles For Process Development And IND ReadinessObserve how a milestone-driven risk management strategy streamlines cell therapy development, reduces uncertainty, and aligns early decisions with long-term commercialization and regulatory success.
-
![GettyImages-1409734937-3d-rendering-rna-dna]( "Synthetic DNA As An Alternative For Scalable Viral Vector Production")
Synthetic DNA As An Alternative For Scalable Viral Vector ProductionEnzymatically synthesized DNA is assessed as a plasmid alternative, showing comparable viral vector yield, quality, and purification, while improving scalability and regulatory flexibility.
-
![cell-therapy-GettyImages-1494029118]( "Expanding The Capabilities Of Targeted Integration")
Expanding The Capabilities Of Targeted IntegrationSee the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.
-
![GettyImages-2150753936 cancer cell]( "Anticoagulant Selection Influences T Cell Purity And Yield In Whole Blood Isolation")
Anticoagulant Selection Influences T Cell Purity And Yield In Whole Blood IsolationLithium heparin reduces T cell purity to below 50% and spikes CD15+ contamination in whole blood workflows. See which anticoagulants consistently deliver above 90% CD3+ purity.
-
Simplify Process Scale-Up With An Innovative Single-Use Bioreactor
Consistent cell growth and protein yields from 5 L to 5,000 L show how a unified bioreactor design can simplify scale-up, reduce risk, and accelerate upstream process development in bioproduction.
-
![GettyImages-2168491650 technology, sustainability, dna]( "Science With Purpose: Advancing Sustainability In Biopharma Testing")
Science With Purpose: Advancing Sustainability In Biopharma TestingLearn how biopharma labs are cutting animal use, energy, and paper waste while maintaining GMP compliance — with specific data on 85% labor reductions and 1 ton of CO2e saved annually.
NEWSLETTER ARCHIVE
- 07.03.26 -- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- 07.02.26 -- New Podcast Episodes: A Midyear Look At Life Sciences, Derisking CNS Drug Development, In Vivo Gene Editing
- 07.02.26 -- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- 07.01.26 -- In Vivo Gene Editing Is Moving From Promise To Proof
- 06.30.26 -- Cell Therapy Without The Cells: Building A Therapeutic Secretome
- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
